nach oben

International Journal of Clinical Oncology

Erschienen in:

14.09.2015 | Original Article

Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy

verfasst von: Susumu Saigusa, Yuji Toiyama, Koji Tanaka, Yasuhiro Inoue, Koichiro Mori, Shozo Ide, Hiroki Imaoka, Mikio Kawamura, Yasuhiko Mohri, Masato Kusunoki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

CD26 is a transmembrane glycoprotein whose role in various types of malignancies, along with the potential therapeutic and diagnostic targets, has been evaluated. Preoperative chemoradiotherapy (CRT) is an effective tool for local control of rectal cancer, but the rate of disease recurrence remains high. The aim of this study was to clarify the association between CD26 expression and rectal cancer after preoperative CRT.

Methods

A total of 85 patients with rectal cancer who had undergone preoperative CRT were enrolled in this study. We investigated CD26 expression in residual tumors and the surrounding stromal tissue using immunohistochemistry. Additionally, stromal CD26 gene expression was assessed by real-time quantitative polymerase chain reaction.

Results

Patients with high CD26 expression in cancer tissue more frequently had serosal invasion, vascular invasion, and a poor pathological response. High expression of CD26 in the tumor stroma was significantly correlated with histology and tumor recurrence. High CD26 expression in the stroma, but not the tumor itself, was significantly correlated with a poor prognosis. Patients expressing CD26 in the tumor stroma, based on transcriptional analysis, also had a significantly poorer prognosis than those without the expression. In multivariate analysis, lymph node metastasis and high stromal CD26 expression were identified as independent prognostic factors in patients with rectal cancer after neoadjuvant CRT.

Conclusion

Stromal CD26 expression after preoperative CRT was significantly associated with tumor recurrence and prognosis in rectal cancer patients. Our data suggest that stromal CD26 plays an important role and is a potential therapeutic target in tumor relapse.

Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMed

van den Brink M, Stiggelbout AM, van den Hout WB et al (2004) Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 22:3958–3964CrossRefPubMed

Guillem JG, Chessin DB, Cohen AM et al (2005) Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241:829–836 (discussion 836–828) CrossRefPubMedPubMedCentral

Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123CrossRefPubMed

Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701CrossRefPubMed

Kelly T (2005) Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8:51–58CrossRefPubMed

Cordero OJ, Salgado FJ, Nogueira M (2009) On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 58:1723–1747CrossRefPubMed

Kikkawa F, Kajiyama H, Shibata K et al (2005) Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751:45–51CrossRefPubMed

Lam CS, Cheung AH, Wong SK et al (2014) Prognostic significance of CD26 in patients with colorectal cancer. PLoS One 9:e98582CrossRefPubMedPubMedCentral

10.

Ayude D, de la Paez Cadena M, Cordero OJ et al (2003) Clinical interest of the combined use of serum CD26 and alpha-l-fucosidase in the early diagnosis of colorectal cancer. Dis Markers 19:267–272CrossRefPubMed

11.

de la Haba-Rodriguez J, Macho A, Calzado MA et al (2002) Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma 49:307–311PubMed

12.

Cordero OJ, Imbernon M, Chiara LD et al (2011) Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol 2:245–261CrossRefPubMedPubMedCentral

13.

Pang R, Law WL, Chu AC et al (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6:603–615CrossRefPubMed

14.

Dang NH, Aytac U, Sato K et al (2003) T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 121:857–865CrossRefPubMed

15.

Cro L, Morabito F, Zucal N et al (2009) CD26 expression in mature B-cell neoplasia: it’s possible role as a new prognostic marker in B-CELL. Hematol Oncol 27:140–147CrossRefPubMed

16.

Carlucci F, Marinello E, Tommassini V et al (2009) A 57-gene expression signature in B-cell chronic lymphocytic leukemia. Biomed Pharmacother 63:663–671CrossRefPubMed

17.

Havre PA, Abe M, Urasaki Y et al (2009) CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer 101:983–991CrossRefPubMedPubMedCentral

18.

Yamaguchi U, Nakayama R, Honda K et al (2008) Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 26:4100–4108CrossRefPubMed

19.

Lu Z, Qi L, Bo XJ et al (2013) Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. J Res Med Sci 18:647–652PubMedPubMedCentral

20.

Khin EE, Kikkawa F, Ino K et al (2003) Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol 188:670–676CrossRefPubMed

21.

Kajiyama H, Kikkawa F, Ino K et al (2003) Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade. Adv Exp Med Biol 524:245–248CrossRefPubMed

22.

Sun YX, Pedersen EA, Shiozawa Y et al (2008) CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 25:765–776CrossRefPubMed

23.

Tan CW, Lee YH, Tan HH et al (2014) CD26/DPPIV down-regulation in endometrial stromal cell migration in endometriosis. Fertil Steril 102(167–177):e169

24.

Saigusa S, Toiyama Y, Tanaka K et al (2011) Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol 38:655–663CrossRefPubMed

25.

Saigusa S, Inoue Y, Tanaka K et al (2013) Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy. Mol Clin Oncol 2:99–104PubMedPubMedCentral

26.

Ryan R, Gibbons D, Hyland JM et al (2005) Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47:141–146CrossRefPubMed

27.

Gonzalez-Gronow M, Kaczowka S, Gawdi G et al (2008) Dipeptidyl peptidase-IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci 13:1610–1618CrossRefPubMed

28.

Havre PA, Abe M, Urasaki Y et al (2008) The role of CD26/dipeptidyl peptidase-IV in cancer. Front Biosci 13:1634–1645CrossRefPubMed

29.

Sedo A, Stremenova J, Busek P et al (2008) Dipeptidyl peptidase-IV and related molecules: markers of malignancy? Expert Opin Med Diagn 2:677–689CrossRefPubMed

30.

O’Brien P, O’Connor BF (2008) Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 1784:1130–1145CrossRefPubMed

31.

Scanlan MJ, Raj BK, Calvo B et al (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 91:5657–5661CrossRefPubMedPubMedCentral

32.

Chen WT, Kelly T (2003) Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 22:259–269CrossRefPubMed

33.

Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91:439–442CrossRefPubMed

34.

Moehrle MC, Schlagenhauff BE, Klessen C et al (1995) Aminopeptidase M and dipeptidyl peptidase-IV activity in epithelial skin tumors: a histochemical study. J Cutan Pathol 22:241–247CrossRefPubMed

35.

Wilson MJ, Haller R, Li SY et al (2005) Elevation of dipeptidyl peptidase-IV activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J Urol 174:1124–1128CrossRefPubMed

36.

Bogenrieder T, Finstad CL, Freeman RH et al (1997) Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase-IV in benign and malignant human prostate tissue. Prostate 33:225–232CrossRefPubMed

37.

Wesley UV, McGroarty M, Homoyouni A (2005) Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 65:1325–1334CrossRefPubMed

38.

Femia AP, Raimondi L, Maglieri G et al (2013) Long-term treatment with Sitagliptin, a dipeptidyl peptidase-IV inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 133:2498–2503CrossRefPubMed

39.

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458CrossRefPubMed

Titel: Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy
verfasst von: Susumu Saigusa
Yuji Toiyama
Koji Tanaka
Yasuhiro Inoue
Koichiro Mori
Shozo Ide
Hiroki Imaoka
Mikio Kawamura
Yasuhiko Mohri
Masato Kusunoki
Publikationsdatum: 14.09.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0902-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

Clinical trials of antiangiogenic therapy for hepatocellular carcinoma

Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer

A population-based study on the associations between chronic periodontitis and the risk of cancer

Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up

Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie